Testosterone Cypionate Rebound Effects When Stopping: What Actually Happens

What rebound means when testosterone cypionate stops

Testosterone cypionate is an oil-soluble ester of testosterone. Injected deep into the gluteal muscle, it is absorbed slowly from the oil depot and split to free testosterone. The label allows dosing every 2 to 4 weeks and gives a half-life of about 8 days [1].

The label says that during administration of exogenous androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary LH, and at large doses also FSH [1]. Among the withdrawal symptoms it describes after abrupt discontinuation, the label lists hypogonadotropic hypogonadism, which means low testosterone from low pituitary signalling [1].

The Depo-Testosterone label describes these withdrawal symptoms in individuals taking supratherapeutic doses; it does not describe a testosterone surge after stopping [1]. The label also states that drug dependence in people using approved doses for approved indications has not been documented [1].

How long does the low-testosterone window last?

The Depo-Testosterone label gives no timeline for a man's own serum testosterone to return to baseline after cypionate is stopped [1]. The recovery endpoint measured in large numbers is sperm output, and much of that data comes from men whose testosterone was used for contraception rather than replacement.

Liu and colleagues pooled 30 studies and 1,549 healthy men with normal testosterone who received androgen or androgen-progestin regimens as experimental male contraception [2]. Median time for sperm concentration to recover to 20 million per mL was 3.4 months. Recovery was 67 percent within 6 months, 90 percent within 12 months, 96 percent within 16 months and 100 percent within 24 months. Faster recovery went with shorter-acting testosterone, shorter treatment, older age and a higher baseline sperm count [2]. These were healthy men on contraception regimens, not men with hypogonadism on replacement doses.

An earlier World Health Organization multicentre study gave 271 healthy fertile men 200 mg testosterone enanthate weekly [5]. After the injections stopped, the estimated median time from azoospermia to at least 20 million per mL was 3.7 months, and the median time to each man's own mean baseline sperm concentration was 6.7 months [5].

Fertility after testosterone-related infertility

Two retrospective studies looked at men who presented with infertility while on testosterone. Kohn and colleagues followed 66 men who stopped testosterone and received high-dose hCG plus a selective estrogen receptor modulator; 46 of them (70 percent) reached a total motile count above 5 million within 12 months [3]. Azoospermic men were less likely to get there than men with cryptozoospermia (64.8 percent versus 91.7 percent), and older age and longer testosterone use predicted slower recovery [3].

Wenker and colleagues treated 49 men who had azoospermia or severe oligospermia while on exogenous testosterone with hCG 3,000 units subcutaneously every other day plus clomiphene, tamoxifen, anastrozole or recombinant FSH [4]. Spermatogenesis returned or sperm counts improved in 47 of them (95.9 percent), average 4.6 months, with a mean first density of 22.6 million per mL, and there was no difference by type of testosterone [4]. Both studies are retrospective, with no untreated comparison group.

The Endocrine Society guideline recommends against starting testosterone therapy in men who plan to have children in the near term, and recommends monitoring symptoms, serum testosterone, hematocrit and prostate cancer risk during the first year of treatment [6].

Mood, sleep and the rest of the withdrawal list

The label's withdrawal list is mostly neuropsychiatric: depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia and decreased libido, alongside hypogonadotropic hypogonadism [1]. A case-control study of men who used non-prescribed anabolic steroids found a similar pattern persisting long after cessation: 33 former users, average 2.5 years after stopping, had lower median total testosterone than 30 controls (14.4 versus 18.8 nmol/L), 27.2 percent were below the lower reference limit, and they reported more depressive symptoms (24.2 percent), erectile dysfunction (27.3 percent) and decreased libido (40.1 percent) [7]. That study population used supraphysiologic doses outside clinical care, not replacement doses.

Gynecomastia and breast tissue

The Depo-Testosterone label says gynecomastia may develop and occasionally persists in patients treated for hypogonadism [1]. Estrogens stimulate breast tissue growth and androgens inhibit it, and most gynecomastia results from deficient androgen action or excessive estrogen action in the breast [8]. Aromatase is the enzyme that converts androgens to estrogens [9].

Medicines affected when testosterone is started or stopped

The label says androgens may increase sensitivity to oral anticoagulants and the anticoagulant dose may need to be reduced; INR and prothrombin time should be monitored more often when testosterone is started or stopped [1]. The label also says the metabolic effects of androgens may decrease blood glucose and therefore insulin requirements in diabetic patients [1].

When low testosterone has an underlying cause

The label's primary hypogonadism indication covers testicular failure from cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy, and its hypogonadotropic indication covers gonadotropin or LHRH deficiency or pituitary-hypothalamic injury from tumors, trauma or radiation [1]. In these conditions low testosterone has a cause apart from the injections themselves.

In men whose suppression came from anabolic steroid use rather than prescribed replacement, a review found that symptomatic hypogonadism can follow, depending on dose, duration and type of steroid used, and that management options discussed in the literature are judicious testosterone replacement, hCG and selective estrogen receptor modulators [12]. That review set out to pool studies but found no quality studies that met its inclusion criteria, so it reflects expert practice rather than trial evidence [12].